Cargando…
Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspecti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257301/ https://www.ncbi.nlm.nih.gov/pubmed/35813101 http://dx.doi.org/10.1097/HS9.0000000000000736 |
_version_ | 1784741315973480448 |
---|---|
author | Skalt, Daniela Moertl, Bernhard von Bergwelt-Baildon, Michael Schmidt, Christian Schoel, Wolfgang Bücklein, Veit Weiglein, Tobias Dreyling, Martin Berger, Karin |
author_facet | Skalt, Daniela Moertl, Bernhard von Bergwelt-Baildon, Michael Schmidt, Christian Schoel, Wolfgang Bücklein, Veit Weiglein, Tobias Dreyling, Martin Berger, Karin |
author_sort | Skalt, Daniela |
collection | PubMed |
description | The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r/r DLBCL patients were estimated. The budget impact ranged from €39,419,562; €53,426,514 (min; max) in year 0 to €122,104,097; €165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of €65,987,823; €89,558,611 (min; max) and €204,485,031; €277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r/r DLBCL. |
format | Online Article Text |
id | pubmed-9257301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-92573012022-07-07 Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany Skalt, Daniela Moertl, Bernhard von Bergwelt-Baildon, Michael Schmidt, Christian Schoel, Wolfgang Bücklein, Veit Weiglein, Tobias Dreyling, Martin Berger, Karin Hemasphere Article The aim was to assess the incremental costs of chimeric antigen receptor (CAR) T-cell therapy (axicabtagene ciloleucel, tisagenlecleucel) compared with standard of care in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) from the German third-party payer perspective. A budget impact model was established over a 6-year period. Estimation of the third-line population: partitioned survival model based on outcome data from peer-reviewed literature, a top-down approach based on population forecasts, and age-standardized incidences. Cost data were derived from the controlling department of a tertiary hospital and a German cost-of-illness study. In the scenario analysis, the budget impact of treating second-line DLBCL patients was calculated. One-way deterministic sensitivity analyses were conducted to test the robustness of the model. For the period 2021-2026, 788-867 (minimum population, min) and 1,068-1,177 (maximum population, max) adult third-line r/r DLBCL patients were estimated. The budget impact ranged from €39,419,562; €53,426,514 (min; max) in year 0 to €122,104,097; €165,763,001 (min; max) in year 5. The scenario analysis resulted in a budget impact of €65,987,823; €89,558,611 (min; max) and €204,485,031; €277,567,601 (min; max) for years 0 and 5, respectively. This budget impact analysis showed a significant but reasonable financial burden associated with CAR T-cell therapy for a limited number of patients requiring individualized care. Further, this study presents challenges and future needs in data acquisition associated with cost analysis in personalized medicine. For comprehensive economic discussions, complementary cost-effectiveness analyses are required to determine the value of innovative therapies for r/r DLBCL. Lippincott Williams & Wilkins 2022-07-04 /pmc/articles/PMC9257301/ /pubmed/35813101 http://dx.doi.org/10.1097/HS9.0000000000000736 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Skalt, Daniela Moertl, Bernhard von Bergwelt-Baildon, Michael Schmidt, Christian Schoel, Wolfgang Bücklein, Veit Weiglein, Tobias Dreyling, Martin Berger, Karin Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany |
title | Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany |
title_full | Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany |
title_fullStr | Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany |
title_full_unstemmed | Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany |
title_short | Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany |
title_sort | budget impact analysis of car t-cell therapy for adult patients with relapsed or refractory diffuse large b-cell lymphoma in germany |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257301/ https://www.ncbi.nlm.nih.gov/pubmed/35813101 http://dx.doi.org/10.1097/HS9.0000000000000736 |
work_keys_str_mv | AT skaltdaniela budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT moertlbernhard budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT vonbergweltbaildonmichael budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT schmidtchristian budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT schoelwolfgang budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT buckleinveit budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT weigleintobias budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT dreylingmartin budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany AT bergerkarin budgetimpactanalysisofcartcelltherapyforadultpatientswithrelapsedorrefractorydiffuselargebcelllymphomaingermany |